| Quarter | Prior | Estimate | Actual | Surprise | |
|---|---|---|---|---|---|
| Q3 2019 Pre-Market | EPS: REV: | -0.27 | |||
| Q2 2019 After-Hours | EPS: REV: | -0.26 | |||
| Q1 2019 Pre-Market | EPS: REV: | -0.33 | |||
| Q4 2018 Pre-Market | EPS: REV: | -0.27 | -0.30 | ||
| Q3 2018 Pre-Market | EPS: REV: | -0.24 | -0.30 | -0.27 | -10% |
| Q2 2018 After-Hours | EPS: REV: | -0.30 | -0.34 | -0.26 | -23.53% |
| Q1 2018 Pre-Market | EPS: REV: | -0.34 | -0.28 | -0.33 | 17.86% |
| Q4 2017 Pre-Market | EPS: REV: | -0.36 630.61M | -0.26 | -0.27 | 3.85% |
| Q3 2017 Pre-Market | EPS: REV: | -0.34 18K | -0.29 | -0.24 | -17.24% |
| Q2 2017 Pre-Market | EPS: REV: | -0.41 | -0.37 | -0.30 | -18.92% |
Data powered by Benzinga Pro Calendars - Start your FREE TRIAL today!
News Coverage
- Warren Buffett Gives Thumbs-Up To New Execs, Notes Earnings Impact From Kraft Heinz In Annual Berkshire Hathaway Letter
- Intuit Analysts React To Tax Software Maker's Q2 Beat
- No Sauce In Domino's Earnings, But This Chart Is Looking Red
- Dropbox Holds 'Margin Expansion Opportunity,' BofA Says In Upgrade
- The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs